• Rofim

  Participated · Equity · Sep 2025

  Rofim operates a digital tele-expertise platform that connects hospital clinicians to facilitate remote consultations and diagnostic collaboration. Positioned as a leader in French hospital telemedicine, the company already works with a large network of healthcare institutions and plans to onboard 400 additional establishments within the next year. Rofim’s technology enables secure video consultations and clinical data sharing, aiming to improve care pathways and reduce patient transfer times. With fresh capital, the company intends to accelerate product development and begin deployment across other European markets. The three co-founders remain majority shareholders, underscoring continued founder control. The firm previously secured €4.4 million in 2021 and has now strengthened its balance sheet with the new raise. No revenue or user metrics were disclosed in the article, but the company emphasizes its market-leading position in hospital telemedicine in France.

• Provepharm life Solutions

  Participated · Equity · Sep 2021

  Provepharm Life Solutions identifies new therapeutic uses for mature molecules, with a focus on antidotes and surgical dyes. Its platform redefines purity requirements for active ingredients to maximize therapeutic potential and explore untouched indications. The company developed a patented synthesis method for methylene blue, enabling marketing authorizations in more than 30 countries. Provepharm is using recent funding to hire staff in France and the United States and to expand its laboratories in Marseille. The firm is headquartered in Marseille with an operation in Philadelphia, employs over 90 people, and reported turnover of €48.5m in 2020. It was founded in 1998 and is led by CEO Michel Feraud. Provepharm Life Solutions is an independent pharmaceutical and life‑sciences group created in 1998 and based in Marseille, France. The company provides pharmaceutical‑grade methylene blue in 25 countries and focuses on revitalizing known molecules. Its strategy is to develop its product range, apply its expertise to other molecules, and strengthen its international business. Provepharm ended 2018 with record results and completed its first company acquisition in October 2018, integrating a new product portfolio. Over the next months the company plans to accelerate growth and strengthen its US subsidiary to expand its international presence.

No current team members are available.